APYX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Apyx Medical Inc (APYX) is not a strong buy at the moment for a beginner, long-term investor. While the company has potential with its unique Renuvion technology and positive analyst coverage, the financial performance shows declining net income and EPS, and technical indicators are neutral to bearish. The lack of significant positive trading signals, coupled with no recent news or political trading activity, suggests waiting for stronger entry signals or improved financial performance.
The MACD histogram is negative and contracting (-0.0621), RSI is neutral at 32.951, and moving averages are converging. The stock is trading below the pivot level of 3.719, with key support at 3.28 and resistance at 3.99. Overall, the technical indicators suggest a neutral to bearish trend.
Roth Capital initiated coverage with a Buy rating and a $6 price target, citing the unique Renuvion technology and expected adoption driven by weight-loss trends.
Declining financial performance in Q3 2025, with net income down -57.81% YoY and EPS dropping -64.29% YoY. No significant trading trends from insiders or hedge funds. No recent news or political trading activity.
In Q3 2025, revenue increased by 12.10% YoY to $12.88M, but net income dropped to -$1.98M (-57.81% YoY), and EPS fell to -0.05 (-64.29% YoY). Gross margin improved to 64.43% (+6.43% YoY), indicating some operational efficiency.
Roth Capital initiated coverage with a Buy rating and a $6 price target, highlighting the company's unique Renuvion technology and expected adoption driven by weight-loss trends.
